Home > Publications Database > Will adaptive deep brain stimulation for Parkinson's disease become a real option soon? A Delphi consensus study. > print

001     278562
005     20250525001315.0
024 7 _ |a 10.1038/s41531-025-00974-5
|2 doi
024 7 _ |a pmid:40325017
|2 pmid
024 7 _ |a pmc:PMC12052990
|2 pmc
024 7 _ |a altmetric:176826415
|2 altmetric
037 _ _ |a DZNE-2025-00595
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Guidetti, Matteo
|b 0
245 _ _ |a Will adaptive deep brain stimulation for Parkinson's disease become a real option soon? A Delphi consensus study.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1747918573_22615
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a While conventional deep brain stimulation (cDBS) treatment delivers continuous electrical stimuli, new adaptive DBS (aDBS) technology provides dynamic symptom-related stimulation. Research data are promising, and devices are already available, but are we ready for it? We asked leading DBS experts worldwide (n = 21) to discuss a research agenda for aDBS research in the near future to allow full adoption. A 5-point Likert scale questionnaire, along with a Delphi method, was employed. In the next 10 years, aDBS will be clinical routine, but research is needed to define which patients would benefit more from the treatment; second, implantation and programming procedures should be simplified to allow actual generalized adoption; third, new adaptive algorithms, and the integration of aDBS paradigm with new technologies, will improve control of more complex symptoms. Since the next years will be crucial for aDBS implementation, the research should focus on improving precision and making programming procedures more accessible.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a Bocci, Tommaso
|b 1
700 1 _ |a De Pedro Del Álamo, Marta
|b 2
700 1 _ |a Deuschl, Guenther
|b 3
700 1 _ |a Fasano, Alfonso
|b 4
700 1 _ |a Martinez-Fernandez, Raul
|b 5
700 1 _ |a Gasca-Salas, Carmen
|b 6
700 1 _ |a Hamani, Clement
|b 7
700 1 _ |a Krauss, Joachim K
|b 8
700 1 _ |a Kühn, Andrea A
|0 P:(DE-2719)2811089
|b 9
|u dzne
700 1 _ |a Limousin, Patricia
|b 10
700 1 _ |a Little, Simon
|b 11
700 1 _ |a Lozano, Andres M
|b 12
700 1 _ |a Maiorana, Natale V
|b 13
700 1 _ |a Marceglia, Sara
|b 14
700 1 _ |a Okun, Michael S
|b 15
700 1 _ |a Oliveri, Serena
|b 16
700 1 _ |a Ostrem, Jill L
|b 17
700 1 _ |a Scelzo, Emma
|b 18
700 1 _ |a Schnitzler, Alfons
|b 19
700 1 _ |a Starr, Philip A
|b 20
700 1 _ |a Temel, Yasin
|b 21
700 1 _ |a Timmermann, Lars
|b 22
700 1 _ |a Tinkhauser, Gerd
|b 23
700 1 _ |a Visser-Vandewalle, Veerle
|b 24
700 1 _ |a Volkmann, Jens
|b 25
700 1 _ |a Priori, Alberto
|b 26
773 _ _ |a 10.1038/s41531-025-00974-5
|g Vol. 11, no. 1, p. 110
|0 PERI:(DE-600)2819218-7
|n 1
|p 110
|t npj Parkinson's Disease
|v 11
|y 2025
|x 2373-8057
856 4 _ |u https://pub.dzne.de/record/278562/files/DZNE-2025-00595%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/278562/files/DZNE-2025-00595.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/278562/files/DZNE-2025-00595%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/278562/files/DZNE-2025-00595.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:278562
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811089
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:43:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:43:48Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:43:48Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)5000008
|k AG Kühn
|l Movement Disorders (Parkinson's disease, Dystonia)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000008
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21